-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ij3PhXu4VqzjQRwSDP/Eqbwkq697wL/CpYNzSelzCFfUtKrop38aRw3gKIrwmX5p
 ENfTcTEL2Z0BCM06HEEO2w==

<SEC-DOCUMENT>0001075880-09-000021.txt : 20090408
<SEC-HEADER>0001075880-09-000021.hdr.sgml : 20090408
<ACCEPTANCE-DATETIME>20090408080416
ACCESSION NUMBER:		0001075880-09-000021
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090408
FILED AS OF DATE:		20090408
DATE AS OF CHANGE:		20090408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		09738790

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20090408.htm
<DESCRIPTION>FORM 6K 2009 04 08
<TEXT>
<html>
  <head>
    <title>form6k20090408.htm</title>
<!-- Licensed to: Novogen Laboratories Pty Ltd-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 5%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5%; FONT-FAMILY: Times New Roman">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">______________________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">SECURITIES
EXCHANGE ACT OF 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">For the
month of April, 2009</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Commission
File Number <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">________________</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">140 Wicks
Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(Address
of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">___________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Form 20-F
<font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Form 40-F <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7): <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>No <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf </font>by the undersigned, thereunto duly
authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">/s/&#160;&#160;Ron
Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Ronald
Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Company
Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Date
8 April, 2009</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="TEXT-ALIGN: right">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><br>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right"><img src="novogenlogo.jpg" alt="Novogen logo"></div>
    <div style="TEXT-ALIGN: right">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">ASX
&amp; MEDIA RELEASE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">8
APRIL, 2009</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">GLYCOTEX&#8217;
INVESTIGATIONAL COMPOUND GLYC-101 ACHIEVES ACCELERATED WOUND CLOSURE BASED ON
INTERIM ANALYSIS.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited&#8217;s subsidiary, Glycotex, Inc., has made the following
announcement:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Rockville,
MD &#8211; 7 April, 2009 - Glycotex, Inc. today announced the completion of a
scheduled interim analysis in a Phase II study evaluating the effect of
investigational GLYC-101 gel on complete wound closure and cosmetic outcomes in
cosmetic surgery patients undergoing carbon dioxide laser skin resurfacing on
the lower eyelid area.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
interim analysis was conducted after 26 subjects completed the study. The
comparison of each active arm to placebo with respect to the primary endpoint
(time to complete wound closure) shows positive results when considering the
full dataset of patient data from all treatment combinations.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Specifically,
the efficacy outcomes were statistically significantly different when comparing
GLYC-101 0.1% and GLYC-101 1.0% groups to placebo (<font style="DISPLAY: inline; FONT-STYLE: italic">p</font> values are 0.0062 and
0.0331, respectively).&#160; These interim results suggest that the&#160;time to
wound closure will be shorter for eyelids treated on the active arms when
compared to placebo in the final analysis.&#160;&#160;Assessment of safety data
is ongoing.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">This
ongoing Phase II randomised, double-blind, placebo-controlled clinical study
will continue enrolment to approximately 48 patients at one clinical trial site
in Beverly Hills, California.&#160;&#160;Patients are randomised to receive
either GLYC-101 0.1%, GLYC-101 1.0%, or placebo gel on one lower eyelid, and a
different test article on the other lower eyelid applied topically to the
laser-ablated area immediately following the laser procedure and for four
consecutive days thereafter for a total of five applications. The primary
efficacy endpoint of the study is time to complete wound healing, and the
secondary efficacy point is cosmetic outcomes, including
scarring.&#160;&#160;The study is observing the effects of the topical agent
over the course of one month following the initial treatment with the
investigational compound (GLYC-101 gel) or placebo.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
GLYC-101</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">A
previous Phase II Pilot Study, investigating clinical outcomes and safety
parameters of GLYC-101 gel at two doses compared to placebo, was completed in
April 2008.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">GLYC-101
is being developed to stimulate and modulate the natural cascade of wound
healing activities of several cell populations. &#160;The product candidate is a
topical gel to be applied directly on the wound surface.&#160; In May 2006,
Glycotex completed a Phase&#160;II clinical trial of GLYC-101 in Australia, in
which GLYC-101 produced a statistically significant rate of wound area reduction
versus combined placebo and standard care in patients with chronic venous
ulcers.&#160;&#160;The results provided proof-of concept and dose-ranging
information for GLYC-101.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
strategic priorities for GLYC-101 include wound healing following laser
ablation, burn wounds, surgical wounds, venous ulcers, and diabetic
ulcers.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
Glycotex, Inc.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Glycotex,
Inc. is a US based development stage biopharmaceutical company focused on
discovering and developing therapies intended to accelerate human wound healing
and tissue repair across a wide range of human applications.&#160;&#160;It has
licensed from Novogen Limited certain patent rights and know-how to use and
exploit its technology in a wide range of wound healing
applications.&#160;&#160;Glycotex, Inc. is an 81 percent owned subsidiary of
Novogen Limited.&#160;&#160;For more information, visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.glycotexinc.com</font>.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">Under </font><font style="DISPLAY: inline; FONT-STYLE: italic">U.S.</font><font style="DISPLAY: inline; FONT-STYLE: italic"> law, a new drug cannot be marketed
until it has been investigated in clinical trials and approved by the FDA as
being safe and effective for the intended use. Statements included in this press
release that are not historical in nature are "forward-looking statements"
within the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. You should be aware that our actual results could
differ materially from those contained in the forward-looking statements, which
are based on management's current expectations and are subject to a number of
risks and uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays in the
development and/or FDA approval, or the failure to obtain such approval, of our
product candidates; uncertainties in clinical trial results; our inability to
maintain or enter into, and the risks resulting from our dependence upon,
collaboration or contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution of any
products; competitive factors; our inability to protect our patents or
proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice; and
one-time events. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking
statements.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div style="TEXT-ALIGN: right">&#160;</div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogenlogo.jpg
<DESCRIPTION>NOVOGEN LOGO
<TEXT>
begin 644 novogenlogo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`!"`,\#`2(``A$!`Q$!_\0`
M'``!`0$!`0`#`0````````````<&!0@!`P0"_\0`1A```0,#`@,&`@4'"`L`
M`````0`"`P0%$08A!Q)!$R(Q46&!%'$(%3*1H187(S1T@K$S.%)RL\'1X4)&
M5%9B=9*3HL+2_\0`&@$!``,!`0$```````````````(#!`$%!O_$`#(1``$#
M`@4"!`4"!P````````$``A$#!!(3(3%!47$%%(&A(C)2D<%AL2,S0D/1X?'_
MV@`,`P$``A$#$0`_`/5*(B(B(B(B(B(B^BKJ8Z5L3I7!H?(V,$]2XX`^_"^]
M8OC#/4TG#ZXU=$XMJ*9\,['#H6RL.?P70),*%1^!A=T"VB+/Z$U12:NT[3W.
MD+0]PY9X0<F*0>+3_$>8(6@0B-"NM<'@.;L41$7%)$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$12'B%Q%O.FM;/H:6*GEM\,<4TC'1DN+3]KO`[;*#WA@DK1;6S[
ME^73W5>1?DM-PI[K;*6OHG\]-41B1A]".OJL;Q8U5<M+TUIDM?89J:GLY.U9
MS=W;PW]5US@T8BH4J+ZM3+;NMZB*8ZLXBUIOCK!HJ@;<KFUQ9)*X]QCAX@#;
M..I)`'JCGANZ[0MWUS#!MOT`_54Y9SB/1FOT%?Z=K>9SJ.1S1ZM;S#\0L74#
MBQ14YJ^VM-86CF=2L8.;'C@;#/EL5VM`:^IM7"HM=RI307B-KFS4S_!X&SN7
M.^W5IW'JN-JC$`=%.M8ORW.:0X<P9A><>'FLJW1E\;64N9*63#*FG)P)69_!
MPZ'_`!*]=V"\45^M%-<K9*):6H;S-/4>;2.A!V(\UXOU/:I+'J&XVR7/-2SN
MC!/4`['W&"J)]'_6#[-J,66KEQ;KB[#`X[1S?Z)'];[)_=\EOK,#AB"^3\-N
MG4:F0_8^Q7IQ$6%L>J+A>>)5WM5*8#9;;&&R.#,N=+L,<W3?FV_X5B+@%]/3
MI.J!Q'`DK=(IQKOB.^UW9MATS0_6E\<>4M`)9&<9Q@;DXW/0=3T7X#'Q9%*:
MKXBTN>!GX4-;S'TSC&?=0-43`U6AMD\M#GD-G:3$JK(I[H'B$^\W*2R:AH?J
MR^1DM[,YY92!D@`^!QOC)SYJA.(:"7$`#<D]%)K@X2%16H/H.PO"(I5=.(MW
MOEVGM?#VV-KG0Y;+6S?R;3G`(W`QL=R=_)?$C.+-,P3MEM%6?$T[6M&/3)`^
M7BH9HX$K1Y%X'QN#3T)U5619_0UQO5SLG;ZDMK;=7-E='V;2>\T>#L;XSOU/
MGU66XA:GU'0:QM5CTTVD=+64YD`G;XN#CUSL,!2+P!B*J9;/?4-,$2)YTT_5
M4E%+^UXK?[/9?^L+>Z:=='62E.H&0,NG*>W;`<LSD^'MA=:Z>%RK0RQ.('L5
MTT46TQQ5N#]7?!7YM.+;+4/I62QQEIC?S$,R<XQMO\\JTKC'A^H7;BUJ6Q`J
M<B418&35=Q;Q?BTV.Q^K7TW:GN=_FY"?'/F%OE(.!V5=2DZG&+D2BC-YH:>Y
M<?Q15L39::>W.CD8[P(,3E9E(I_YQU/^PG^S<JZO'=:;$D%Y'TE?/#6NGTAJ
MNNT5>)3V+W&:W2/.S@23@'U&^/,.7]?2#_4=/_MG_P`KL\8M+R7BRQW:V!S;
MQ:LSPN9]IS1@D#&^1C(]1ZK`\0=3,U9HO3%P#>2H;6]E41_T)!RY]CXCYJI_
MPM+#Z+T;89]9ERW?4.[P=?7]U7^(%TDLNC+O7P9$L4!#"#@ASNZ#[9S[+,<"
M['#;]'Q7-S>:LN)=*Z1P[P9G`;GVSZDK0<3;?)<]!WFF@`,I@[1H]6D.V]=E
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MIIN7]1%0YH.`9.7=H_>V64X602V+AM=-0U>375@FKG.D))(:#RY^9!/NIS8[
MK-=^&%ATG2/'Q%9<WP.V^S&"'[^F7Y_=7H&]6ELND*VTT3.5AHGT\3&[8[F&
MC^"P5!_$,<+ZVU>!9TR_^X03V'^Y^RGW`&SAULKM15K"^X5LSF"5^[N48+CG
MU=G[E6E+^`%U94Z4GMLCP*JBG<3&1@ACMQ\]^8*H+E",`A6>)EWFGAW7VX]E
M(>/EL;1TUMU/1?HJZDG;&Y[-BX>+22/(MQ\B0NOQ6U%)!PPCJ:?FCFNC(HQR
MG!:'MYG;_P!4$>ZY_P!(2XQBP4%FC<365M2U[6MW(:WK[N+0%]O%RQS#A521
MM([6UB%[R/#`;R./_EGV5;Y!?AZ+9;PYMOG;8C';_JU7#6PPZ?T?;Z:)@;-+
M&V>=W5TC@"?NV'LM0L]P_O,%]TC;:N!P+A$V*5N<EDC0`X'W_`A:"0D,<1X@
M%7LC"(V7E7!>:KLS>3*^5)M>5E-;^,^EJJMF9!3QTC^>20X:W)>-S\RNQP7U
M#<]1V"OJ;Q4_$31U;HV'D:WE;R@XV`\UQ.(5NI+MQBTQ0W&!L])-2/#XW9P[
M!>>GJ`J7NQL#AU6^VHY%P^G4X:Z8[<+>MUGIIS@UM]MQ).`!.W_%=]8]G#31
M['M>VQTX<TAP/._8@Y!^TM@KFXOZEAK9.F3/K'X4`T9I>/5>F-9T8:/C&7!T
ME*_P+9!G`SY'P/\`DJ%PAU1)?+));[F[%YMKNPJ&.V<YHV#B#]Q]1ZKB\!?]
M:_\`F)_O7T\1:*HT9K"DUM:8'/II7"&XQ,SN#MS>^W[P!ZJAOP@/'JO3JG/J
M/MG;[M[QMZ_ND_\`..I_V$_V;E75&Z>KAK_I`V^KI7B2GGMPDC<.K3$2%9%9
M2Y[K%>@C+!^D?E%-9;%<W<<X;P*.3ZL;1\AJ-N7FY",?>52D4W-Q0L]*J:4Q
MR"/NB\^<1.']RH-4A^GJ"KJ;75S,J3'`WF;"_F[P(Z#J/0D=%Z#11J4Q4$%7
M6=X^T>7,UGA#N,'P4AO6CM0Z2U#-?-`\L]+.>:HMSSX[Y(`/B/'&.\,E5Y%U
M[`[=5T+AU`G#J#N#L5)GZ]UO5,%-1:(GAK=@Z2;F[,$]=P/XKH\/M!5M#>)=
M1ZKJ6U=\F&0T8+8B1@G/@3C88V`\%2$413UEQE7.O(:64FAH.\;_`'/"+F:E
ML=%J*S5-LN<0DIYFX]6.Z.!Z$+IHK=EA(#A!4%X,:#K[+Q!NLETIY1!;0603
M.9ADSG9`<WS[N3MX9"O2(AU)/5&RUC:?#1`[3/Y4JU;H6[VW4;]3:%F9'6/.
M9Z-Q`$F3EV,[8.,D'KN"OK_.!K7LC3_D+4_'X^WW^S\?+'_LJRBJRX/PF%O%
M[B:!68'1L3,^VZE>C-#7:OU`-3:\E;-<&D.IZ5I!;$1X$XV&.@'4Y.ZJ,\,=
M1!)#.QLD4C2Q['#(<#L05_:*;6!H@*BO</KNQ.XV'`[*-R:0U5H.YS5>B'MN
M%KE)<^AE.X'08SN1T(P?1?K;Q"UC-$Z%FA*OXD=TEW.&Y]V_WJLHH"EA^4PM
M!O14UK,#CUU!]8W4_P""^G;EIS3E5!>*<4\\]296Q\X<0WE`WQ\ER^)-!J"+
MB!9+Y8+0^XBCIG-(R`WF+G9!W'1RJB+N4,(:H>=>:SJY`DSVUT4L_*_B'_N0
MS_O?YK>Z6K;E<+)!47JA%!7.+N>G!SRX)QO\L+K(I!I'*IJ50\0&`=I_RIQP
M<LMRLYU&+G1RTPGKC)$7X[[=]QNMW>+;37BUU5OKH^TIJAAC>WT/4>H\5^Q$
M:T`0E2LZI4S-BH1P\TA>[#Q1IVUE'5OM](R:*.L<W]&6<IY,'IG/AYY5W1%R
MG3#!`5EW=NNGA[QJ!"(B*:RHB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
+B(B(B(B(B(B+_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
